Eflornithine plus sulindac

DRUG2 trials

Sponsors

Cancer Prevention Pharmaceuticals, Inc., SWOG Cancer Research Network

Conditions

Colorectal NeoplasmsFamilial Adenomatous Polyposis

Phase 3

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

WithdrawnNCT01245816

Cancer Prevention Pharmaceuticals, Inc.Familial Adenomatous Polyposis

Start: 2011-03-31End: 2013-06-30Updated: 2015-04-24

S0820, Adenoma and Second Primary Prevention Trial

Active, not recruitingNCT01349881

SWOG Cancer Research NetworkColorectal Neoplasms

Start: 2013-08-23End: 2032-02-01Updated: 2026-04-02

Related Papers

SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac): A randomized, double-blind, placebo-controlled phase III clinical trial.

Journal of Clinical Oncology2015-05-20